Cargando…
An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently...
Autores principales: | Liu, Fei, Feng, Canbin, Xu, Shiqi, Wu, Qiang, Tang, Jian, Chen, Yan, Xu, Ruisheng, Chen, Fuliang, Gao, Ni, Xu, Zhengzheng, Gu, Shihui, Lan, Yang, Zhou, Haibo, Hu, Xinde, Wang, Xiaojing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769940/ https://www.ncbi.nlm.nih.gov/pubmed/35094871 http://dx.doi.org/10.1016/j.vaccine.2022.01.030 |
Ejemplares similares
-
Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant
por: Poon, Rosana Wing-Shan, et al.
Publicado: (2021) -
Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer
por: Connelly, Guinevere G., et al.
Publicado: (2022) -
Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants
por: Mi, Taotao, et al.
Publicado: (2022) -
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022) -
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)